|
|
Vaccine Detail
|
MEDI-534 |
| Vaccine Information |
- Vaccine Name: MEDI-534
- Target Pathogen: Human Respiratory Syncytial Virus
- Target Disease: Respiratory tract disease
- Manufacturer: MedImmune LLC
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- HN
gene engineering:
- Type: Recombinant protein preparation
- Description: Bovine parainfluenza virus type 3 genome was substituted with HN glycoproteins.(Yang et al., 2013)
- Detailed Gene Information: Click Here.
- F protein
gene engineering:
- Type: Recombinant protein preparation
- Description: Substituting the human PIV3 F and HN glycoproteins to express RSV F protein (Yang et al., 2013).
- Detailed Gene Information: Click Here.
- Preparation: The bovine parainfluenza virus type 3 (PIV3) genome was substituted with human PIV3 F and HN glycoproteins engineered to express RSV F protein.(Yang et al., 2013)
- Immunization Route: intranasal immunization
- Description: MEDI 534 is a live attenuated type 3 vectored RSV vaccine intransally administered and engineered to express RSV F, neutralizing antibodies against both RSV A and B subtypes.(Yang et al., 2013)
|
| Host Response |
|
|
| References |
|
|
|
